Medtronic has acquired assets of US-based privately held medical device company Aptus Endosystems in a transaction valued at nearly $110m.
Headquartered in California, Aptus develops Heli-FX and Heli-FX Thoracic EndoAnchor systems that are designed to treat complex aortic disease.
Featuring an endovascular deployed anchor that attaches to a variety of aortic endografts to the native vessel wall, the two systems bear the CE Mark for distribution in the European Union and are cleared by US Food and Drug Administration for distribution in the US.
Medtronic Cardiac and Vascular Group Aortic business vice-president Daveen Chopra said: "The Heli-FX and Heli-FX Thoracic EndoAnchor systems strongly align with our strategy to invest in treatments that address complex aortic disease with a vision to treat disease of the entire aorta."
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
The acquisition will also enable Medtronic to distribute the TourGuide Steerable Sheath, a device with an adjustable tip that allows for quick access and delivery of peripheral vascular products to the most challenging anatomy in the US and Europe.
Medtronic, which will add the Aptus business to its Aortic and Peripheral Vascular division within the Cardiac and Vascular Group, also aims to continue the Anchor Registry, a prospective post-market registry evaluating the Heli-FX Aortic Securement system.
In addition, the company seeks to secure approval for <10mm infrarenal proximal neck indication for Endurant with the use of the Heli-FX EndoAnchor system.
In a separate transaction, Medtronic acquired CardioInsight Technologies for $93m. CardioInsight will become part of the Medtronic Atrial Fibrillation (AF) Solutions business in the Cardiac Rhythm and Heart Failure division.
Medtronic AF Solutions business vice-president Reggie Groves said: "CardioInsight will broaden and enhance the existing AF Solutions programme at Medtronic, and will provide meaningful clinical and economic solutions for patients, hospitals, physicians and payers."
The company developed the CardioInsight ECVUE system, which non-invasively generates images of the electrical activity of the heart by combining body surface electrical data with 3D anatomical data, and subsequently reconstructs and displays 3D maps and other useful measures of cardiac electrical activity.
Revenue generated from the CardioInsight product line will be included as part of the Cardiac Rhythm and Heart Failure division within the Cardiac and Vascular Group.